Osteoporosis Medication FOSAMAX PLUS 5600IU Now Registered

Merck Sharp & Dohme New Zealand (MSDNZ) has gained registration for its osteoporosis medication FOSAMAX PLUS™ 5600 IU.

MSDNZ Managing Director, Alister Brown, says "This will be welcome news for the many doctors who have been calling for increased Vitamin D supplementation in osteoporosis medication.

"Merck & Co has long recognised the importance of Vitamin D in improving bone health and it was the first company in the world to develop a bisphosphonate treatment containing Vitamin D – FOSAMAX PLUS 2800IU which was launched in New Zealand in 2007.

Click here for more.